エプコリタマブ（遺伝子組換え）
Epcoritamab (Genetical Recombination)


エプコリタマブは，CD3ε鎖及びCD20に対する遺伝子組換え二重特異性モノクローナル抗体であり，抗CD3ε鎖抗体の可変部はマウス抗体に，その他はヒトIgG1に由来し，抗CD20抗体はヒトIgG1に由来する．抗CD3ε-H鎖の4つのアミノ酸残基が置換（L242F，L243E，D273A，F413L）され，C末端のK455は除去されている．また，抗CD20-H鎖の4つのアミノ酸残基が置換（L239F，L240E，D270A，K414R）され，C末端のK452は除去されている．エプコリタマブは，CHO細胞により産生される．エプコリタマブは，454個のアミノ酸残基からなる抗CD3ε-H鎖（γ1鎖）1本，215個のアミノ酸残基からなる抗CD3ε-L鎖（λ鎖）1本，451個のアミノ酸残基からなる抗CD20-H鎖（γ1鎖）1本及び214個のアミノ酸残基からなる抗CD20-L鎖（κ鎖）1本で構成される糖タンパク質（分子量約149,000）である．

Epcoritamab is a recombinant bispecific monoclonal antibody against CD3ε chain and CD20, which is composed of anti-CD3ε chain antibody whose variable regions are derived from mouse antibody and other regions are derived from human IgG1, and anti-CD20 antibody derived from human IgG1. In the anti-CD3ε-H-chain, the amino acid residues are substituted at 4 positions (L242F, L243E, D273A, F413L), and K455 at the C-terminus is deleted. In the anti-CD20-H-chain, the amino acid residues are substituted at 4 positions (L239F, L240E, D270A, K414R), and K452 at the C-terminus is deleted. Epcoritamab is produced in CHO cells. Epcoritamab is a glycoprotein (molecular weight: ca. 149,000) composed of an anti-CD3ε-H-chain (γ1-chain) consisting of 454 amino acid residues, an anti-CD3ε-L-chain (λ-chain) consisting of 215 amino acid residues, an anti-CD20-H-chain (γ1-chain) consisting of 451 amino acid residues, and an anti-CD20-L-chain (κ-chain) consisting of 214 amino acid residues.

[2134641-34-0]